Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
説明 | CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM). |
ターゲット&IC50 | PLK4:0.26 nM(ki) |
In vitro | CFI-400945, a potent and selective PLK4 inhibitor.?Cancer cells treated with CFI-400945 exhibit effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects, and cell death[1]. |
In vivo | Oral administration of CFI-400945 to mice bearing human cancer xenografts results in the significant inhibition of tumor growth at doses that are well tolerated[1]. |
分子量 | 534.65 |
分子式 | C33H34N4O3 |
CAS No. | 1338806-73-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 100 mg/mL (187.04 mM)
H2O: Insoluble
DMSO: 100 mg/mL (187.04 mM), Heating to 50℃ is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ocifisertib(CFI-400945 free base) 1338806-73-7 Cell Cycle/Checkpoint PLK CFI400945 free base CFI-400945 Ocifisertib CFI-400945 free base CFI 400945 free base CFI400945 CFI 400945 Inhibitor inhibitor inhibit